Cargando…

Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes

BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investig...

Descripción completa

Detalles Bibliográficos
Autores principales: ODABAS, Faruk Omer, UCA, Ali Ulvi, AKDAG, Turan, DEMİRDÖGEN, Filiz, ALTAS, Mustafa, TOKGOZ, Osman Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173210/
https://www.ncbi.nlm.nih.gov/pubmed/35195231
http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202
_version_ 1784721982464458752
author ODABAS, Faruk Omer
UCA, Ali Ulvi
AKDAG, Turan
DEMİRDÖGEN, Filiz
ALTAS, Mustafa
TOKGOZ, Osman Serhat
author_facet ODABAS, Faruk Omer
UCA, Ali Ulvi
AKDAG, Turan
DEMİRDÖGEN, Filiz
ALTAS, Mustafa
TOKGOZ, Osman Serhat
author_sort ODABAS, Faruk Omer
collection PubMed
description BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. METHODS: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. RESULTS: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. CONCLUSIONS: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS.
format Online
Article
Text
id pubmed-9173210
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academia Brasileira de Neurologia - ABNEURO
record_format MEDLINE/PubMed
spelling pubmed-91732102022-12-08 Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes ODABAS, Faruk Omer UCA, Ali Ulvi AKDAG, Turan DEMİRDÖGEN, Filiz ALTAS, Mustafa TOKGOZ, Osman Serhat Arq Neuropsiquiatr Articles BACKGROUND: Characterized by demyelination, inflammation and axonal damage, multiple sclerosis (MS) is one of the most common disorders of central nervous system led by the immune system. There is an urgent and obvious need for biomarkers for the diagnosis and follow-up of MS. OBJECTIVE: To investigate serum levels of sestrin2 (SESN2), a protein that responds to acute stress, in MS patients. METHODS: A total of 85 participants, 40 patients diagnosed previously with relapsing-remitting MS and 45 healthy controls, were included. Serum SESN2 parameters were investigated in blood samples drawn from each participant in the patient and control groups. RESULTS: SESN2 levels were significantly lower in MS patients than in controls (z: -3.06; p=0.002). In the ROC analysis of SESN2, the predictive level for MS was 2.36 ng/mL [sensitivity, 72.50%; specificity, 55.56%; p=0.002; area under the curve (AUC)=0.693]. For the cut-off value in both groups, SESN2 was an independent predictor for MS [Exp (B)=3.977, 95% confidence interval (95%CI) 1.507-10.494 and p=0.013]. CONCLUSIONS: The decreased expression of SESN2 may play a role in MS pathogenesis, and SESN2 could be used as a biomarker for MS and as immunotherapeutic agent to treat MS. Academia Brasileira de Neurologia - ABNEURO 2022-02-21 /pmc/articles/PMC9173210/ /pubmed/35195231 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Articles
ODABAS, Faruk Omer
UCA, Ali Ulvi
AKDAG, Turan
DEMİRDÖGEN, Filiz
ALTAS, Mustafa
TOKGOZ, Osman Serhat
Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title_full Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title_fullStr Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title_full_unstemmed Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title_short Possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
title_sort possible roles of sestrin2 in multiple sclerosis and its relationships with clinical outcomes
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173210/
https://www.ncbi.nlm.nih.gov/pubmed/35195231
http://dx.doi.org/10.1590/0004-282X-ANP-2021-0202
work_keys_str_mv AT odabasfarukomer possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes
AT ucaaliulvi possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes
AT akdagturan possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes
AT demirdogenfiliz possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes
AT altasmustafa possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes
AT tokgozosmanserhat possiblerolesofsestrin2inmultiplesclerosisanditsrelationshipswithclinicaloutcomes